NK-1 receptor antagonists for the treatment of cancer
US5990125A · kind A · utility
9Cited by
0References
1Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 17, 1997 |
| Grant date | Nov 23, 1999 |
| Priority date | — |
| Expiry date | Jan 17, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4458
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of certain NK-1 receptor antagonists (e.g., substance P receptor antagonists) to treat cancer patients, particularly cancer patients afflicted with a small cell lung carcinoma, APUDoma, astrocytoma, neuroendocrine tumor or extrapulmonary small cell carcinoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.